Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a common diabetes drug work safely in kidney patients?

NCT ID NCT02895750

Disease control Sponsor: Centre Hospitalier Universitaire, Amiens Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This phase 2 trial tested the safety and effectiveness of metformin extended release (XR) in 12 adults with type 2 diabetes and mild to moderate chronic kidney disease (stages 1 to 3). Participants took metformin XR tablets for 6 to 12 weeks, and researchers monitored their blood glucose levels continuously. The goal was to see if the drug could control blood sugar without causing harm, especially to the kidneys.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
metformin extended release (XR)
What this could lead to
If successful, this could show that metformin XR is safe and effective for managing blood sugar in type 2 diabetes patients with mild to moderate kidney disease.
What could go wrong
This is a small, early-phase study with only 12 participants, so results may not apply broadly. Metformin can rarely cause lactic acidosis, especially in kidney disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

12 people

The number who actually took part.

Started

Aug 2017

Finished

Oct 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Type 2 diabetes patients aged between 18 and 80 years requiring metformin (and any other antidiabetic treatment) Exclusion Criteria: * Pregnancy and lactation * Hyperlactatemia (\> 2.5 mmol/L) * No creatinine levels available since 3 months * Severe hepatic insufficiency * No liver function parameters available * Need of investigation with iodized contrast media * Hypersensitivity to metformin

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Renal insufficiency, chronic are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Renal insufficiency, chronic

Contacts and locations

Locations

  • CHU Amiens Picardie

    Amiens, 80054, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.